#Germany #London #MOYOM #APHRANEL® #Expert2Expert

MOYOM's Commitment to Regenerative Aesthetics in Europe

In a significant step forward for regenerative aesthetics, MOYOM, the biotechnology company behind APHRANEL®, has achieved two critical milestones in its European expansion strategy: securing EU-MDR certification for its flagship product, APHRANEL®, and announcing a strategic scientific collaboration with Expert2Expert (E2E), led by renowned aesthetic surgeon Dr. Patrick Trévidic.

EU-MDR Certification: A Gateway to European Markets

On July 7, 2026, MOYOM received official certification under the European Medical Device Regulation (EU-MDR) from BSI UK, one of the world's leading regulatory bodies. This certification confirms that APHRANEL® meets the highest European standards concerning quality, safety, and clinical performance, marking a pivotal moment in MOYOM's journey toward establishing a strong presence in the European market.

However, for MOYOM, regulatory approval is not merely an endpoint but the beginning of an even more extensive scientific journey. As Guangming Lin, MOYOM's CEO, emphasizes, "Achieving market access is just the first challenge. Gaining the trust of medical professionals is the crucial next step."

Collaborating with Experts to Foster Innovation

Following the certification milestone, MOYOM entered into a strategic partnership with Expert2Expert (E2E), a scientific organization boasting over 20 years of experience in supporting leading players in aesthetic medicine. This collaboration is poised to create a long-lasting platform for regenerative aesthetics in Europe, enriching the medical community through anatomical research, advanced studies involving cadaver donors, clinical evidence gathering, physician education, and scientific publications.

With Dr. Patrick Trévidic at the helm, E2E will leverage its vast expertise in evidence-based research while maintaining complete scientific independence. The partnership signifies a shared commitment to innovation while ensuring that all scientific endeavors remain unbiased and objective.

The Vision for the Future

Dr. Patrick Trévidic, who brings over 35 years of experience in aesthetic surgery and research, will play a vital role in this alliance. His extensive background includes clinical research, international teaching roles, and more than 75 peer-reviewed publications. This collaboration integrates MOYOM's Calcium Hydroxylapatite technology with E2E's scientific proficiency to form a foundation centered on evidence, education, and clinical advancement.

Both MOYOM and E2E have set clear objectives for this partnership, focusing on developing scientific programs that encompass further anatomical studies, clinical research across Europe, medical education initiatives, and global scientific collaborations. The ultimate goal is to enhance the credibility of APHRANEL® within the medical community throughout Europe.

Patrice Delobel, PhD, MOYOM's Director of Medical and Marketing in Europe, echoes this sentiment, stating, "When I chose to join MOYOM, it was never just about overseeing the launch of APHRANEL® in Europe. I aimed to help establish a scientific platform that doctors can rely on for many years to come. This collaboration with E2E, guided by Dr. Trévidic, is one of the first and most important steps toward achieving that vision."

A Commitment to Evidence-Based Innovation

Dr. Trévidic and his team at E2E share MOYOM's vision while ensuring complete independence in their scientific undertakings. "Scientific advancement is never achieved by a single person or company alone; it thrives through collaboration, curiosity, and a continuous quest for deeper understanding," he states, reinforcing the need for collective effort in their mission.

These two significant milestones lay the groundwork for MOYOM's long-term scientific commitment. Their philosophy, Care Lifetime Value, embodies a multi-faceted approach to long-term scientific initiatives:

• - Care: Supporting patients through sound science, safe practices, and meaningful education.
• - Lifetime: Building enduring trust with physicians via continuous learning and partnerships.
• - Value: Making a tangible impact within the healthcare ecosystem, connecting physicians, patients, scientific partners, and healthcare communities.

Driven by the Care Lifetime Value philosophy, MOYOM will continue to focus on scientific research, medical education, collaboration, and evidence-gathering to shape the future of regenerative aesthetics.

Because while innovation may begin in the lab, science changes clinical practice, and trust transforms the future. Evidence builds trust; trust drives adoption; and adoption enhances patient lives.